While marketed as non-sedating, these medications can still cause drowsiness in some individuals and may interact with other medications
Wegovy distributes into body tissues, and individuals with higher body mass may experience slightly different pharmacokinetics compared to those with lower body weight
None of these are certain signs of muscle loss on their own, but if you're noticing them alongside low protein intake, it's worth taking the gap seriously
Ozempic is still the GLP-1 king, but Lilly is rapidly gaining market share, with its Q2 2024 sales reaching $3.01 billion compared to Novo Nordisks $5.38 billion
It has approvals from US FDA, PMDA (Japan), ANVISA (Brazil), ISO certifications, and others
Notably, histologic fibrosis stage improved by 1 point in 24% of patients on resmetirom compared to 10% on placebo, a signal that is not commonly seen with weight-neutral agents in such a short timeframe [26]